Transcript of conference call on the Company s Q4 and financial year ended 31st March, 2026 Earnings
CLEAN · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Clean Science reported Q4 FY26 stand-alone revenue of INR 193 crores (up 8% QoQ driven by volume) with EBITDA margin of 46% and PAT margin of 40%. Full-year revenue declined 12% to INR 796 crores due to loss of a key FMCG customer (4-MAP product) and pricing pressure. Consolidated revenue was INR 246 crores with 33% EBITDA margin. The subsidiary Clean Fino-Chem achieved its first positive EBITDA of INR 7-8 crores in Q4, with HQ/Catechol plant at 10-15% utilization and expected optimization in 1-2 quarters. HALS business showed strong momentum with over 1,000 tonnes volume in Q4 (up from ~350 tonnes 8 quarters ago), 50% export mix, and INR 460/kg blended realization. Management voluntarily reduced promoter bonus to less than 1% of PBT (reversing ~INR 11 crores). FY27 capex guidance is INR 80-100 crores, with Performance Chemical 2 expected by September 2026. Management declined to provide FY27 guidance citing macro uncertainty and geopolitical factors.
The company showed sequential improvement in Q4 with strong HALS traction offsetting weakness in core MEHQ business. Promoter bonus reduction signals alignment with shareholders. However, management's refusal to give FY27 guidance due to macro uncertainty suggests a cautious near-term outlook.